Segall Bryant & Hamill LLC Takes $19.02 Million Position in Repligen Co. (NASDAQ:RGEN)

Segall Bryant & Hamill LLC acquired a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 132,143 shares of the biotechnology company's stock, valued at approximately $19,021,000. Segall Bryant & Hamill LLC owned approximately 0.24% of Repligen at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Repligen by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock valued at $734,251,000 after buying an additional 56,723 shares during the period. LPL Financial LLC increased its holdings in Repligen by 47.6% during the 4th quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company's stock worth $4,873,000 after acquiring an additional 10,395 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of Repligen during the 4th quarter valued at $667,000. KLP Kapitalforvaltning AS bought a new position in shares of Repligen in the fourth quarter worth $1,555,000. Finally, Sei Investments Co. increased its holdings in shares of Repligen by 12.7% in the fourth quarter. Sei Investments Co. now owns 219,604 shares of the biotechnology company's stock worth $31,610,000 after purchasing an additional 24,662 shares during the period. Institutional investors own 97.64% of the company's stock.

Insider Transactions at Repligen

In other Repligen news, Director Margaret Pax bought 250 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 1.20% of the company's stock.

Repligen Trading Down 2.7 %

Repligen stock traded down $3.71 during mid-day trading on Friday, hitting $133.41. The company's stock had a trading volume of 856,653 shares, compared to its average volume of 673,469. The business has a 50 day moving average price of $154.21 and a 200-day moving average price of $148.19. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $184.98. The stock has a market cap of $7.49 billion, a price-to-earnings ratio of -261.59, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to analysts' expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, analysts forecast that Repligen Co. will post 1.72 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on RGEN shares. TD Cowen initiated coverage on Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 target price for the company. Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective on the stock. JPMorgan Chase & Co. lifted their target price on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. StockNews.com cut shares of Repligen from a "hold" rating to a "sell" rating in a research note on Friday, February 21st. Finally, Royal Bank of Canada raised their price objective on shares of Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Repligen has a consensus rating of "Hold" and a consensus price target of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.